Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes Care 29:1220-1226, 2006
DOI: 10.2337/dc05-2465
© 2006 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow patientINFORMation
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shepherd, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shepherd, J.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Clinical Care/Education/Nutrition
Original Article

Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes

The Treating to New Targets (TNT) study

James Shepherd, MD1, Philip Barter, MD, PHD2, Rafael Carmena, MD3, Prakash Deedwania, MD4, Jean-Charles Fruchart, PHARMD, PHD5, Steven Haffner, MD6, Judith Hsia, MD7, Andrei Breazna, PHD8, John LaRosa, MD9, Scott Grundy, MD, PHD10, David Waters, MD11 for the Treating to New Targets Investigators

1 Department of Vascular Biochemistry, University of Glasgow, Glasgow, U.K.
2 The Heart Research Institute, Department of Medicine, University of Sydney, Sydney, Australia
3 Endocrinology Department, Clinic University Hospital, University of Valencia, Valencia, Spain
4 Cardiology Division, Veterans Affairs Central California Health Care, University of California San Francisco School of Medicine, San Francisco, California
5 Lipoprotein and Atherosclerosis Research Unit, Institut National de la Santé et de la Recherche Médicale, Pasteur Institute, Lille, France
6 Department of Medicine, University of Texas Health Science Center, San Antonio, Texas
7 Division of Cardiology, George Washington University Medical Center, Washington, DC
8 Biometrics Department, Pfizer, New York, New York
9 State University of New York Downstate Medical Center, State University of New York Health Science Center, Brooklyn, New York
10 Center for Human Nutrition, Departments of Clinical Nutrition and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas
11 Division of Cardiology, School of Medicine, San Francisco General Hospital, University of California San Francisco School of Medicine, San Francisco, California

Address correspondence and reprint requests to James Shepherd, Biochemistry, Royal Infirmary, Glasgow, G4 OSF, U.K. E-mail: jshepherd{at}gri-biochem.org.uk

OBJECTIVE—The Treating to New Targets study showed that intensive lipid-lowering therapy with atorvastatin 80 mg/day provides significant clinical benefit beyond that afforded by atorvastatin 10 mg/day in patients with stable coronary heart disease (CHD). The objective of our study was to investigate whether similar benefits of high-dose intensive atorvastatin therapy can be achieved in patients with CHD and diabetes.

RESEARCH DESIGN AND METHODS—A total of 1,501 patients with diabetes and CHD, with LDL cholesterol levels of <130 mg/dl, were randomized to double-blind therapy with either atorvastatin 10 (n = 753) or 80 (n = 748) mg/day. Patients were followed for a median of 4.9 years. The primary end point was the time to first major cardiovascular event, defined as death from CHD, nonfatal non–procedure-related myocardial infarction, resuscitated cardiac arrest, or fatal or nonfatal stroke.

RESULTS—End-of-treatment mean LDL cholesterol levels were 98.6 mg/dl with atorvastatin 10 mg and 77.0 mg/dl with atorvastatin 80 mg. A primary event occurred in 135 patients (17.9%) receiving atorvastatin 10 mg, compared with 103 patients (13.8%) receiving atorvastatin 80 mg (hazard ratio 0.75 [95% CI 0.58–0.97], P = 0.026). Significant differences between the groups in favor of atorvastatin 80 mg were also observed for time to cerebrovascular event (0.69 [0.48–0.98], P = 0.037) and any cardiovascular event (0.85 [0.73–1.00], P = 0.044). There were no significant differences between the treatment groups in the rates of treatment-related adverse events and persistent elevations in liver enzymes.

CONCLUSIONS—Among patients with clinically evident CHD and diabetes, intensive therapy with atorvastatin 80 mg significantly reduced the rate of major cardiovascular events by 25% compared with atorvastatin 10 mg.

Abbreviations: ADA, American Diabetes Association • CHD, coronary heart disease • TNT, Treating to New Targets


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Find additional patient-related information at:

High Doses of Cholesterol-Lowering Drug Are Beneficial




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2006 by the American Diabetes Association.